MedTrace Logo

DNase Treatment for Dry Eyes

NCT02193490 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2020-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.

Conditions

  • Dry Eye

Interventions

DRUG

DNase

DNase 0.1% eye drops four times a day for 8 weeks

DRUG

Vehicle

Drug vehicle eye drops four times a day for 8 weeks

Sponsors & Collaborators

  • Research to Prevent Blindness

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Sandeep Jain, MD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-10-11
Completion
2017-10-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193490 on ClinicalTrials.gov